KDIGO 2024儿童与成人CKD指南欧洲肾脏最佳实践评论
该评论由欧洲肾脏最佳实践组织撰写,解读KDIGO 2024儿童与成人慢性肾脏病评估与管理指南。评论指出尽管新型疗法在随机对照试验中显示可延缓CKD进展并降低心血管风险,但欧洲CKD诊治仍不理想,呼吁采取紧急行动改善诊疗。
要点
- KDIGO 2024指南提供儿童与成人CKD评估和风险管理的实践步骤。
- SGLT2抑制剂、GLP-1受体激动剂和非甾体类MRA已证实在RCT中减少CKD进展和心血管事件。
- 欧洲CKD诊断与治疗仍不理想,指南应被视为改进诊疗的紧急行动呼吁。
核心结论
- KDIGO 2024 CKD指南应被视为改善欧洲儿童和成人CKD诊断与治疗的紧急行动呼吁。
研究设计与样本
- 本文为欧洲肾脏最佳实践(ERBP)对KDIGO 2024 CKD指南的评论,从欧洲视角审查指南中CKD评估与风险相关章节。
主要发现
- 新型疗法包括SGLT2抑制剂、GLP-1受体激动剂和非甾体类MRA已在多项随机对照临床试验中证明可减少CKD进展及心血管疾病发病率和死亡率。
- 尽管CKD评估已被多个国家/国际肾脏病、心脏病和糖尿病指南与学会强调,欧洲CKD诊断和治疗仍不理想。
临床怎么用
- 临床应参考KDIGO 2024指南中关于CKD评估和风险分层的实践步骤来改善儿童和成人CKD的诊疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Guideline for Identification and Management of Chronic Kidney Disease (CKD) is a welcome development, coming 12 years after the paradigm-changing 2012 guidelines. We are living in an unprecedented era in nephrology with novel therapies, including sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists, now being proven in multiple randomized controlled clinical trials to reduce both the progression of CKD and cardiovascular morbidity and mortality. The KDIGO 2024 CKD Guideline is aimed at a broad audience looking after children and adults with CKD and provide practical and actionable steps to improve care. This commentary reviews the guideline sections pertaining to the evaluation and risk assessment of individuals with CKD from a European perspective. We feel that despite the last guideline being published 12 years ago, and the fact that the assessment of CKD has been emphasized by many other national/international nephrology, cardiology and diabetology guidelines and societies, the diagnosis and treatment of CKD remains poor across Europe. As such, the KDIGO 2024 CKD Guideline should be seen as an urgent call to action to improve diagnosis and care of children and adults with CKD across Europe. We know what we need to do. We now need to get on and do it.
引用
- Iatridi F, Carrero JJ, Cornec-Le Gall E, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease in Children and Adults: a commentary from the European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2025. PMID: 39299913. doi:10.1093/ndt/gfae209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。